

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of **June, 2022**

Commission File Number: **001-38480**

**IMV Inc.**

*(Name of registrant)*

**130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **IMV Inc.**

Date: June 30, 2022

By: /s/ Brittany Davison  
Name: Brittany Davison  
Title: Snr. VP Finance acting as Chief Financial Officer

---

Form 6-K Exhibit Index

**Exhibit  
Number**

**Document Description**

[99.1](#)

[News Release dated June 30, 2022. IMV Announces Annual and Special Meeting of Shareholders Voting Results.](#)

---



### IMV Announces Annual and Special Meeting of Shareholders Voting Results

**DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. – June 30, 2022** -- IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the voting results from its annual and special meeting of shareholders held on June 29, 2022 (the “Meeting”).

Based on the votes received, all resolutions were accepted, including the election of directors, for whom details of the votes are as follows:

| <i>Name of nominee</i> | <i>Votes FOR</i> | <i>% of votes FOR</i> | <i>Votes Withheld</i> | <i>% of votes Withheld</i> |
|------------------------|------------------|-----------------------|-----------------------|----------------------------|
| Michael Bailey         | 27,525,895       | 99.11%                | 246,171               | 0.89%                      |
| Brittany Davison       | 27,582,627       | 99.32%                | 189,439               | 0.68%                      |
| Julia P. Gregory       | 27,144,284       | 97.74%                | 627,782               | 2.26%                      |
| Andrew Hall            | 27,568,568       | 99.27%                | 203,498               | 0.73%                      |
| Michael Kalos          | 27,573,095       | 99.28%                | 198,970               | 0.72%                      |
| Kyle Kovalanka         | 27,569,209       | 99.27%                | 202,856               | 0.73%                      |
| Shermaine Tilley       | 27,333,424       | 98.42%                | 438,641               | 1.58%                      |
| Markus Warmuth         | 27,354,231       | 98.50%                | 417,835               | 1.50%                      |

Andrew Sheldon, former board chair, did not stand for re-election at the meeting. Michael Bailey, recently appointed Chairman of the Board, commented: “On behalf of my fellow board members and the IMV management team, I would like to thank Andy for his exceptional leadership and service to the Company over the past six years. During his tenure at IMV, Andy oversaw a number of important developments including establishing clinical proof of concept for our lead candidate, MVP-S. I know that Andy will be missed by the entire team and we wish him well in his future endeavors.”

Shareholders approved the appointment of PricewaterhouseCoopers, LLP, Chartered Professional Accountants, as independent auditor for the Company for the ensuing year and that the board of directors of the Company be authorized to fix its remuneration.

Shareholders approved an amendment to the Company’s deferred share unit plan (the “DSU Plan”) to increase of the number of Shares reserved for issuance under the DSU Plan by 1,031,250, bringing the share reserve up to 2,000,000 Shares.

The Company would also like to thank Joy Bessenger, who left her position of Senior Vice President, Investor Relations and Corporate Strategy of the Company on June 11, 2022 as part of an organizational realignment.

Please refer to the Circular available on SEDAR at [www.sedar.com](http://www.sedar.com) for more information on the business transacted at the Meeting. A report on voting results will also be filed on SEDAR.

A recording of the meeting will be available on the Company's website under [Events and Presentations](#).

#### **About IMV**

IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company's immune-educating platform: the DPX® technology. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV's lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immunity activator and a universal CD4 T cell helper peptide. These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function. MVP-S treatment has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer was initiated in early 2022. For more information, visit [www.imv-inc.com](http://www.imv-inc.com) and connect with us on [Twitter](#) and [LinkedIn](#).

#### **IMV Forward-Looking Statements**

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as "will", "may", "potential", "believe", "expect", "continue", "anticipate" and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the potential impact of the VITALIZE study and the anticipated date data from such study is available, the Company's ability to advance its development strategy, as well as the prospects, for its lead immunotherapy and its other pipeline of immunotherapy candidates. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release

---

except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, those related to the Company's expected timeline associated with its cash runway; the Company's priorities with MVP-S and its DPX delivery platform, the potential for its delivery platform and the anticipated timing of enrollment and results for its clinical trial programs and studies as others risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).

#### **Investor Relations**

##### **Irina Koffler, Managing Director, LifeSci Advisors**

O: (646) 970-4681

M: (917) 734-7387

E: [ikoffler@lifesciadvisors.com](mailto:ikoffler@lifesciadvisors.com)

#### **Media**

##### **Delphine Davan, Senior Director, Communications and Investor Relations, IMV Inc.**

M: (514) 968 1046

E: [ddavan@imv-inc.com](mailto:ddavan@imv-inc.com)

##### **Madeline Joanis, Senior Account Executive, LifeSci Communications**

M: (603) 479 5267

E: [mjoanis@lifescicomms.com](mailto:mjoanis@lifescicomms.com)

---